The Sai Parenteral’s Limited IPO is set to open on March 24, 2026, offering investors an opportunity to invest in a growing pharmaceutical formulations company with a diversified business model. The IPO size of ₹408.79 crore places it in the mid-sized category, attracting attention from both retail and institutional investors.

Despite operating in a high-growth pharma sector, the IPO is currently witnessing neutral grey market sentiment, which makes it important to analyse the fundamentals, business strengths and risks before making an investment decision.

Let us understand the IPO in detail.

About Sai Parenteral’s Limited

Sai Parenteral’s Limited is engaged in the research, development and manufacturing of pharmaceutical formulations. The company operates through two major verticals:

• Branded Generic Formulations

• Contract Development and Manufacturing Organisation (CDMO) services

This dual business model helps the company maintain a balance between domestic branded sales and global contract manufacturing opportunities.

Product Portfolio and Therapeutic Segments

The company has a diversified product portfolio covering multiple therapeutic areas, including:

• Cardiovascular diseases

• Neuropsychiatry

• Anti-diabetic treatments

• Respiratory disorders

• Antibiotics

• Gastroenterology

• Vitamins and supplements

• Analgesics and dermatology

Its medicines are available in various dosage forms such as:

• Injectables

• Tablets

• Capsules

• Liquid orals

• Ointments

This wide range enables the company to cater to different patient needs and healthcare segments.

Business Model and Revenue Streams

Sai Parenteral generates revenue through two primary channels:

1. Branded Generics Business
The company sells its products to:

• Hospitals

• Government agencies

• Pharmaceutical companies

• Distributors

This segment provides stable and recurring revenue.

2. CDMO Services
The company offers services such as:

• Product development

• Regulatory filings

• Commercial manufacturing

These services are provided to domestic and international clients, offering higher growth potential.

IPO Details of Sai Parenteral

The Sai Parenteral IPO is a Book Built Issue with a total size of ₹408.79 crore.

The issue structure includes:

• Fresh Issue: ₹285.00 crore (0.73 crore shares)

• Offer for Sale (OFS): ₹123.79 crore (0.32 crore shares)

Key IPO dates:

• Opening Date: March 24, 2026

• Closing Date: March 27, 2026

• Allotment Date: March 30, 2026

• Listing Date: April 2, 2026

• Stock Exchanges: NSE & BSE

The IPO is managed by Arihant Capital Markets Limited, while Bigshare Services Private Limited is the registrar.

Price Band and Investment Details

The IPO price band is set at ₹372 to ₹392 per share.

At the upper price band:

• Market Capitalisation: ₹1,731.83 crore

Investment details:

• Lot Size: 38 shares

• Retail Minimum Investment: ₹14,896

• HNI Minimum Investment: ₹2,08,544 (14 lots)

The relatively low entry barrier makes the IPO accessible to retail investors.

Grey Market Premium (GMP) Analysis

The Grey Market Premium (GMP) for Sai Parenteral IPO is currently around ₹0.

This indicates:

• Neutral market sentiment

• Limited expectations of listing gains

Important considerations:

• GMP is unofficial and unregulated

• It depends on market demand and sentiment

• It should not be used as the only investment criterion

Strengths of Sai Parenteral

1. Diversified Business Model
The combination of branded generics and CDMO services provides both stability and growth potential.

2. Wide Therapeutic Coverage
Presence across multiple medical segments reduces dependency on a single therapy area.

3. Strong Pharma Industry Tailwinds
India’s pharmaceutical sector is expanding rapidly, driven by increasing healthcare demand.

4. Export Opportunities
CDMO and global registrations enable the company to tap into international markets.

5. Multiple Dosage Capabilities
The ability to manufacture different dosage forms enhances market reach and flexibility.

Risks and Challenges

1. High Competition
The pharmaceutical industry is highly competitive with many established players.

2. Regulatory Risks
Strict regulations in domestic and international markets can impact operations.

3. Dependence on CDMO Clients
Loss of key clients may affect revenue from the CDMO segment.

4. Zero GMP Signal
The absence of GMP suggests limited listing enthusiasm.

Industry Outlook

The Indian pharmaceutical industry is expected to grow strongly due to:

• Rising healthcare awareness

• Increasing demand for generic medicines

• Government support for domestic manufacturing

The CDMO segment is also gaining momentum globally as companies outsource manufacturing to reduce costs.

Sai Parenteral is well-positioned to benefit from these trends if it continues to expand its product portfolio and global presence.

Investment Perspective

For long-term investors:
Sai Parenteral offers a balanced pharma business model with exposure to both domestic and global markets.

For short-term investors:
With zero GMP, listing gains may be limited.

For moderate-risk investors:
The company’s size and diversification make it a reasonable mid-cap pharma opportunity.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.